J. Med. Chem. 2013, DOI:10.1021/jm400402q).
- CAS Number:
- Mol. Formula:
Novartis investigational drug LDK378, a selective inhibitor of the cancer target anaplastic lymphoma kinase (ALK), shows a marked clinical response in patients with ALK+ non-small cell lung cancer (NSCLC) during the 49th Annual Meeting of the American Society of Clinical Oncology…
View original post 605 more words